REDMOND, WA, January 18, 2022 – Pattern Computer,® Inc. (PCI) released its update this week on its 2021 commitment to “move the needle” on the top five cancer killers worldwide, representing a new level of achievement in computational biology.

Specifically:

  1. Triple negative breast cancer. Both PCI’s Champ A and Champ B drug candidates are in their fourth and fifth round of testing, with the former hopefully entering its final round in Q1 on the east coast, as Champ B returns to one of two labs on the west coast (for tissue reasons) in the same timeframe, for one or two more rounds to close out its tests.
  2. Ovarian cancer. The PCI team has concluded all internal computer runs and candidate drug designs for ovarian cancer. PCI is now ready to begin in vitro testing this quarter.
  3. Colorectal cancer. As a result of intense effort by the bio team, PCI has made very large strides against the world’s largest global data set representing this disease, and have increased predictability overall by 5%. More importantly, the team developed proprietary new mathematics for elucidating and analyzing clusters, resulting in predictability outcomes in selected groupings of 70%, 80% and 100%.
  4. Metastatic Prostate cancer. Thanks to our partners at the Fred Hutch Cancer Research Center, we now have what we deem to be sufficient data on metastatic prostate cancer to allow the Pattern Discovery Engines to do their job, and runs have now begun. We look forward to announcing early results during Q1.
  5. Lung cancer. This disease was actually second, chronologically, in the company’s work queue (after breast cancer), with the firm’s “Sonar” discovery engine revealing unique new correlations in gene expressions. Additional runs using PCI’s “Lennard Island” engine are planned for Q1, hopefully leading to new diagnostics and/or treatments.

“I am proud to say that Pattern Computer has now made new discoveries and strides forward regarding each of the top five global cancer killers. It will take some time to develop, test, and monetize these, but I cannot overstate how proud our whole team is to have come this far, this fast. We hope that everyone shares this pride and excitement as we bring the power of our Discovery Engines against some of the world’s largest problems,” said Mark Anderson, CEO.

About Pattern Computer

Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.

While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.

CONTACT:

Brad Holtz –

301.529.9944 –

bh@patterncomputer.com

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

Copyright © 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engines, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.